GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Meribank Biotech Co Ltd (ROCO:4724) » Definitions » Operating Income

Meribank Biotech Co (ROCO:4724) Operating Income : NT$-110.2 Mil (TTM As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Meribank Biotech Co Operating Income?

Meribank Biotech Co's Operating Income for the six months ended in Jun. 2024 was NT$-46.6 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2024 was NT$-110.2 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Meribank Biotech Co's Operating Income for the six months ended in Jun. 2024 was NT$-46.6 Mil. Meribank Biotech Co's Revenue for the six months ended in Jun. 2024 was NT$130.3 Mil. Therefore, Meribank Biotech Co's Operating Margin % for the quarter that ended in Jun. 2024 was -35.72%.

Warning Sign:

Meribank Biotech Co Ltd operating margin has been in a 5-year decline. The average rate of decline per year is -67%.

Meribank Biotech Co's 5-Year average Growth Rate for Operating Margin % was -67.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Meribank Biotech Co's annualized ROC % for the quarter that ended in Jun. 2024 was -11.98%. Meribank Biotech Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -25.81%.


Meribank Biotech Co Operating Income Historical Data

The historical data trend for Meribank Biotech Co's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Meribank Biotech Co Operating Income Chart

Meribank Biotech Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
Get a 7-Day Free Trial -57.39 -65.97 -91.94 -110.37 -118.51

Meribank Biotech Co Semi-Annual Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -52.54 -57.83 -54.84 -63.68 -46.56

Meribank Biotech Co Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-110.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Meribank Biotech Co  (ROCO:4724) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Meribank Biotech Co's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=-93.116 * ( 1 - 0.6% )/( (574.443 + 971.187)/ 2 )
=-92.557304/772.815
=-11.98 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1062.008 - 88.107 - ( 399.458 - max(0, 126.911 - 570.185+399.458))
=574.443

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1220.942 - 83.981 - ( 165.774 - max(0, 133.934 - 358.789+165.774))
=971.187

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Meribank Biotech Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-95.064/( ( (162.056 + max(63.044, 0)) + (423.617 + max(87.918, 0)) )/ 2 )
=-95.064/( ( 225.1 + 511.535 )/ 2 )
=-95.064/368.3175
=-25.81 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(134.545 + 6.907 + 29.275) - (88.107 + 0 + 19.576)
=63.044

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(131.506 + 10.096 + 51.413) - (83.981 + 0 + 21.116)
=87.918

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Meribank Biotech Co's Operating Margin % for the quarter that ended in Jun. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-46.558/130.328
=-35.72 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Meribank Biotech Co Operating Income Related Terms

Thank you for viewing the detailed overview of Meribank Biotech Co's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Meribank Biotech Co Business Description

Traded in Other Exchanges
N/A
Address
Sector 1, Neihu Road, 1st Floor, No.68, Neihu District, Taipei, TWN, 11493
Meribank Biotech Co Ltd is engaged in Research and development and sales of new cell drugs and also Umbilical cord blood, placenta and umbilical cord mesenchymal stem cells processing, testing and cryopreservation.

Meribank Biotech Co Headlines

No Headlines